Clinical trial NCT02385305: The Effect of Pressure Support Ventilation on Spontaneous Breathing in Anesthetized Subjects
Official title: The Effect of Pressure Support Ventilation on Minute Alveolar Ventilation and End-tidal Carbon Dioxide in Anesthetized Spontaneously Breathing Subjects
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Anesthesia
Keywords: Pressure support ventilation
respiratory drive
Physiology
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2015-03-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The aim of this prospective study is to determine the effect of pressure support ventilation (PSV) on minute alveolar ventilation (MAV) and end-tidal carbon dioxide (ETCO2) in anesthetized spontaneously breathing subjects by observing alterations of respiratory rate (RR), expiratory tidal volume, MAV and ETCO2 at variable levels of pressure support.

Detailed description: Anesthesia induction will be performed with usual anesthetics without any opioids and followed by the placement of a laryngeal mask airway. Optimal anesthesia level will be maintained with inhalation anesthesia so as to obtain a bispectral index of 30 to 50. Subjects will be ventilated with controlled mechanical ventilation (CMV) by the anesthesia ventilator until the presence of spontaneous breathing can be affirmed. A carbon dioxide/flow sensor (Adult Combined CO2/Flow Sensor; Novametrix medical systems INC., Wallingford, CT) will be placed between the LMA and the breathing circuit. The sensor will be connected to a noninvasive cardiac output monitor (NICO; Noninvasive Cardiopulmonary management System, model 7300; Respironics Corp., Murrysville, PA). NICO data (end-tidal CO2 (ETCO2), tidal volume and flow waveforms) will be recorded and stored on a personnel computer. At the start of surgery, the anesthesia care provider will administer opioids to control nociceptive stimuli from surgery. Figure 2 shows the procedural course of the study. Once spontaneous breathing is observed, PSV will be applied with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the PSV is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS. If at any point in the course of the study the subjects ETCO2 is higher than 60 mmHg, obvious body motion is observed or abnormal vital signs \[NIBP; \>160/90 mmHg or \<80/50 mmHg, HR; \>100 mmHg or \<40 mmHg, SpO2; \<94% at a given fraction of inspired O2\] occur, the study will be terminated and routine care will be provided.

Eligibility criteria: Inclusion Criteria:

1. ASA physical status classification I or II
2. Expected to be ventilated with a laryngeal mask airway (LMA)
3. Expected to have anesthesia titrated to insure continued spontaneous breathing

Exclusion Criteria:

1. Patients whose surgery will last less than 70 minutes
2. Obese patients with BMI 30 kg/m2 or higher
3. Patients who will have thoracic or abdominal surgery
4. Patients with gastro-esophageal reflux disease
5. Patients who will needed muscle relaxants or are expected to require controlled ventilation during surgery
6. Patients with chronic obstructive pulmonary disease or asthma
7. Patients with neuromuscular disease or presenting with increased intracranial pressure
8. Patients with major cardiovascular disease, or cerebral vascular disease
9. Abnormal vital signs on the day of admission for surgery \[heart rate (HR); \>100 bpm or \<40 bpm, Noninvasive blood pressure (NIBP); \>180/100 mmHg or \<90/60 mmHg or transcutaneous oxyhemoglobin saturation (SpO2); \<94%\] that are not correctable with his or her routine medication or commonly used pre-operative medication
10. Pregnant women and women less than one month post-partum. Pregnancy will be ruled out by careful history and physical examination. If history is equivocal, the subject will be excluded unless a negative pregnancy test is obtained
11. Emergent cases
12. Chronic opioid use

Primary outcomes:
measure: End-tidal carbon dioxide measured by Capnograph monitor
timeFrame: 0, 5, 10, 15, 20, 25, 30 and 35 min after the initiation of PSV
Secondary outcomes:
measure: Respiratory rate measured by Respiratory monitor
timeFrame: 0, 5, 10, 15, 20, 25, 30 and 35 min after the initiation of PSV
measure: Expiratory tidal volume measured by Respiratory monitor
timeFrame: 0, 5, 10, 15, 20, 25, 30 and 35 min after the initiation of PSV
Other outcomes:
Locations:
Study officials:
affiliation: Massachusetts General Hospital
name: Yandong Jian, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008 Jun;100(6):747-58. doi: 10.1093/bja/aen094. Epub 2008 May 1.
citation: Yamanaka T, Sadikot RT. Opioid effect on lungs. Respirology. 2013 Feb;18(2):255-62. doi: 10.1111/j.1440-1843.2012.02307.x.